Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects

Plasma α‐tocopherol (AT) concentrations are inversely related to cardiovascular (CV) risk; however, intervention studies with AT have failed to show any consistent benefit against CV disease (CVD). Proteomics offers the opportunity to examine novel effects of AT supplementation on protein expression and therefore improve our understanding of the physiological roles of AT. Thus, to investigate the effects of AT supplementation on the plasma proteome of healthy subjects we have undertaken a double‐blind, randomised, parallel design supplementation study in which healthy subjects (n = 32; 11 male and 21 female) consumed AT supplements (134 or 268 mg/day) or placebo capsules for up to 28 days. Plasma samples were obtained before supplementation and after 14 and 28 days of supplementation for analysis of changes in the plasma proteome using 2‐DE and MALDI‐MS. Using semiquantitative proteomics, we observed that proapolipoprotein A1 (identified by MS and Western blotting) was altered at least two‐fold. Using quantitative ELISA techniques, we confirmed a significant increase in plasma apolipoprotein A1 concentration following supplementation with AT which was both time and dose dependent (p < 0.01 after 28 days supplementation with 268 mg AT/day). These data demonstrate the time and dose sensitivity of the plasma proteome to AT supplementation.

[1]  D. Teupser,et al.  Alpha-tocopherol down-regulates scavenger receptor activity in macrophages. , 1999, Atherosclerosis.

[2]  C. Napoli,et al.  Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis. , 2003, Trends in molecular medicine.

[3]  E. Fisher,et al.  Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. , 2004, The Journal of clinical investigation.

[4]  J. Gordon,et al.  Proteolytic processing of human preproapolipoprotein A-I. A proposed defect in the conversion of pro A-I to A-I in Tangier's disease. , 1983, The Journal of biological chemistry.

[5]  R. Collins,et al.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[6]  F Gharahdaghi,et al.  Mass spectrometric identification of proteins from silver‐stained polyacrylamide gel: A method for the removal of silver ions to enhance sensitivity , 1999, Electrophoresis.

[7]  H. Griffiths,et al.  The presence of ascorbate induces expression of brain derived neurotrophic factor in SH‐SY5Y neuroblastoma cells after peroxide insult, which is associated with increased survival , 2005, Proteomics.

[8]  A. Azzi,et al.  Age-dependent increase of collagenase expression can be reduced by alpha-tocopherol via protein kinase C inhibition. , 1999, Free radical biology & medicine.

[9]  R. Stocker,et al.  Dealcoholized red wine decreases atherosclerosis in apolipoprotein E gene-deficient mice independently of inhibition of lipid peroxidation in the artery wall. , 2004, The American journal of clinical nutrition.

[10]  A. Gotto,et al.  Activation of lecithin:cholesterol acyltransferase by a synthetic model lipid-associating peptide. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G. Franceschini,et al.  Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[12]  Lin He,et al.  Comparison of protein precipitation methods for sample preparation prior to proteomic analysis. , 2004, Journal of chromatography. A.

[13]  S. Lamon-Fava,et al.  Regulation of apoA-I gene expression: mechanism of action of estrogen and genistein. , 2004, Journal of lipid research.

[14]  J. Westman,et al.  In vitro reverse cholesterol transport from THP-1-derived macrophage-like cells with synthetic HDL particles consisting of proapolipoprotein A1 or apolipoprotein A1 and phosphatidylcholine. , 1995, Scandinavian journal of clinical and laboratory investigation.

[15]  H. Griffiths,et al.  Oxidation of protein in human low-density lipoprotein exposed to peroxyl radicals facilitates uptake by monocytes; protection by antioxidants in vitro. , 2004, Environmental toxicology and pharmacology.

[16]  H. Lakka,et al.  Six-Year Effect of Combined Vitamin C and E Supplementation on Atherosclerotic Progression: The Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study , 2003, Circulation.

[17]  A. Evans,et al.  Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[18]  S. Yusuf,et al.  Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases , 2000, Current cardiology reports.

[19]  W. Roesler,et al.  Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes. , 2002, The Journal of pharmacology and experimental therapeutics.

[20]  A. Azzi,et al.  Non‐antioxidant molecular functions of α‐tocopherol (vitamin E) , 2002 .

[21]  D. Albanes,et al.  Serum α-Tocopherol and γ-Tocopherol in Relation to Prostate Cancer Risk in a Prospective Study , 2005 .

[22]  P. Shaul.  Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. , 2003 .

[23]  U. R. Acharya,et al.  Potential role of vitamins in chromium induced spermatogenesis in Swiss mice. , 2004, Environmental toxicology and pharmacology.

[24]  D. Arveiler,et al.  The relationship between apolipoprotein AI-containing lipoprotein fractions and environmental factors: the prospective epidemiological study of myocardial infarction (PRIME study). , 2000, Atherosclerosis.

[25]  F. Semeria,et al.  Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. , 2001, Journal of lipid research.

[26]  R. W. Gracy,et al.  Vitamin E prevents oxidation of antiapoptotic proteins in neuronal cells , 2003, Proteomics.

[27]  A. Coats.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[28]  R. Dean,et al.  Apolipoprotein A‐1 interaction with plasma membrane lipid rafts controls cholesterol export from macrophages , 2004 .

[29]  E. Schaefer,et al.  Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. , 2002, Atherosclerosis.

[30]  U. Hellman,et al.  Improvement of an "In-Gel" digestion procedure for the micropreparation of internal protein fragments for amino acid sequencing. , 1995, Analytical biochemistry.

[31]  B. Howard,et al.  Antioxidant Vitamin Supplements and Cardiovascular Disease , 2004, Circulation.

[32]  T. Miki,et al.  NFκB Regulates Plasma Apolipoprotein A-I and High Density Lipoprotein Cholesterol through Inhibition of Peroxisome Proliferator-activated Receptor α* , 2003, Journal of Biological Chemistry.

[33]  Roberto Pastor-Barriuso,et al.  Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.

[34]  R. Wait,et al.  A modified silver staining protocol for visualization of proteins compatible with matrix‐assisted laser desorption/ionization and electrospray ionization‐ mass spectrometry , 2000, Electrophoresis.

[35]  F. Kelly,et al.  Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) , 1996, The Lancet.

[36]  B. G. Brown,et al.  Antioxidant Supplements Block the Response of HDL to Simvastatin-Niacin Therapy in Patients With Coronary Artery Disease and Low HDL , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[37]  P. Puska,et al.  Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. , 1991, The American journal of clinical nutrition.

[38]  B. Staels,et al.  Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. , 2001, The Journal of clinical investigation.

[39]  A. Stocker,et al.  Vitamin E: non-antioxidant roles. , 2000, Progress in lipid research.

[40]  S. Devaraj,et al.  α-Tocopherol and Atherosclerosis , 2001 .

[41]  J. Manson,et al.  Vitamin E consumption and the risk of coronary disease in women. , 1993, The New England journal of medicine.

[42]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[43]  E. Topol,et al.  Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials , 2003, The Lancet.

[44]  M. Eriksson,et al.  Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. , 1999, Circulation.

[45]  S. Yusuf,et al.  Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. , 2002, Diabetes care.

[46]  F. Kelly,et al.  Time course of vitamin E repletion in the premature infant , 1990, British Journal of Nutrition.